Page 321 - medicina-integrativa_compress
P. 321

CAPÍTULO 29  VASCULOPATÍA PERIFÉRICA      317

             16.  Willigendael EM, Teijink JA, Bartelink ML, et al: Influence of  41.  Bauer U: Ginkgo biloba extract in the treatment of arteriopathy of
                smoking on incidence and prevalence of peripheral artery disease.   the lower extremities: A 65-week trial. Presse Med 15:1546, 1986.
                J Vasc Surg 40:1158-1165, 2004.                 42.  Blume J, Kieser M, Holscher U, et al: Placebo-controlled double-
             17.  Jonason T, Bergstrom R: Cessation of smoking in patients with  blind study of the effectiveness of Ginkgo biloba special extract EGb
                intermittent claudication: Effects on the risk of peripheral vascular  761 in trained patients with intermittent claudication. Vasa 25:265,
                complications, myocardial infarction, and mortality. Acta Med   1996.
                Scand 221:253-260, 1987.                        43.  Thomson GJ, Vohra RK, Carr MH, Walker MG: A clinical trial
             18.  Mukherjee D, Yadav JS: Update on peripheral vascular disease:   of Ginkgo biloba extract in patients with intermittent claudication.
                From smoking cessation to stenting. Cleve Clin J Med 68:723-733,  Int Angiol 9:75, 1990.
                2001.                                           44.  Saudreau F, Serise JM, Pillet J, et al: Efficacy of an extract of Ginkgo
             19.  Schillinger M, Exner M, Mlekusch W, et al: Effect of smoking on  biloba in the treatment of chronic obliterative arteriopathies of the
                restenosis during the first year after lower-limb endovascular  lower limbs in stage III of Fontaine’s classification. J Mal Vasc
                interventions. Radiology 231:831-838, 2004.         14:177, 1989.
             20.  Tierney S, Fennessy F, Hayes DB: ABC of arterial and vascular  45.  Rudofsky G: Effect of Ginkgo biloba extract in arterial occlusive
                disease: Secondary prevention of peripheral vascular disease.   disease: Randomized placebo-controlled crossover study.
                BMJ 320:1262-1265, 2000.                            Fortschr Med 105:397, 1987.
             21.  Aguilera CM, Mesa MD, Ramirez-Tortosa MC, et al: Sunflower oil  46.  Schneider B: Ginkgo biloba extract in peripheral arterial diseases:
                does not protect against LDL oxidation as virgin olive oil does in  Meta-analysis of controlled clinical studies. Arzneimittelforschung
                patients with peripheral vascular disease. Clin Nutr 23:673-681,  42:428, 1992.
                2004.                                           47.  Pittler MH, Ernst E: Ginkgo biloba extract for the treatment of
             22.  Sommerfield T, Hiatt WR: Omega-3 fatty acids for intermittent  intermittent claudication: A meta-analysis of randomized trials.
                claudication. Cochrane Database Syst Rev (3)CD003833, 2004.  Am J Med 108:276-281, 2000.
             23.  Carrero JJ, Lopez-Huertas E, Salmeron LM, et al: Daily  48.  Horsch S, Walther C: Ginkgo biloba special extract EGb 761 in the
                supplementation with omega-3 PUFAs, oleic acid, folic acid, and  treatment of peripheral arterial occlusive disease (PAOD): A review
                vitamins B 6 and E increases pain-free walking distance and improves  based on randomized, controlled studies. Int J Clin Pharmacol Ther
                risk factors in men with peripheral vascular disease. J Nutr   42:63, 2004.
                135:1393-1399, 2005.                            49.  Jacobs BP, Browner WS: Ginkgo biloba extract for the treatment
             24.  Burdge GC, Jones AE, Wootton SA: Eicosapentaenoic and  of intermittent claudication: A meta-analysis of randomized trials.
                docosapentaenoic acids are the principal products of alpha-linolenic  Am J Med 108:279-281, 2000.
                acid metabolism in young men. Br J Nutr 88:355-364, 2002.  50.  Bent S, Goldberg H, Padula A, Avins AL: Spontaneous bleeding
             25.  Merchant A, Hu F, Spiegelman D, et al: Dietary fiber reduces  associated with Ginkgo biloba: A case report and systematic review
                peripheral arterial risk in men. J Nutr 133:3658-3663, 2003.  of the literature. J Gen Intern Med 20:657, 2005.
             26.  Hung HC, Merchant A, Willett W, et al: The association between  51.  Ang-Lee MK, Moss J, Yuan CS: Herbal medicines and perioperative
                fruit and vegetable consumption and peripheral arterial disease.  care. JAMA 286:208, 2001.
                Epidemiology 14:659-665, 2003.                  52.  Castano G, Mas R, Arruzazabala ML, et al: Effects of policosanol and
             27.  Aikens JE: Thermal biofeedback for claudication in diabetes:   pravastatin on lipid profile, platelet aggregation and endothelemia in
                A literature review and case study. Altern Med Rev 4:104-110, 1999.  older hypercholesterolemic patients. Int J Clin Pharmacol Res
             28.  Saunders JT, Cox DJ, Teates CD, et al: Thermal biofeedback in   19:105-116, 1999.
                the treatment of intermittent claudication in diabetes: A case   53.  Arruzazabala ML, Valdes S, Mas R, et al: Effect of policosanol
                study. Biofeedback Self Regul 19:337-345, 1994.     successive dose increases on platelet aggregation in healthy
             29.  Arseven A, Guralnik JM, O’Brien E, et al: Peripheral arterial   volunteers. Pharmacol Res 34:181-185, 1996.
                disease and depressed mood in older men and women. Vasc Med  54.  Castano G, Mas Ferreiro R, Fernandez L, et al: A long-term study of
                6:229-234, 2001.                                    policosanol in the treatment of intermittent claudication. Angiology
             30.  McDermott MM, Greenland P, Guralnik JM, et al: Depressive  52:115-125, 2001.
                symptoms and lower extremity functioning in men and women with  55.  Castano G, Mas R, Roca J, et al: A double-blind, placebo-controlled
                peripheral arterial disease. J Gen Intern Med 18:461-467, 2003.  study of the effects of policosanol in patients with intermittent
             31.  Wattanakit K, Willliams JE, Schreiner PJ, et al: Association of anger  claudication. Angiology 50:123-130, 1999.
                proneness, depression, and low social support with peripheral  56.  Castano G, Mas R, Fernandez L, et al: Effects of policosanol and
                arterial disease. The Atherosclerosis Risk in Communities Study.  lovastatin in patients with intermittent claudication: A double-blind
                Vasc Med 10:199-206, 2005.                          comparative pilot study. Angiology 54:25-38, 2003.
             32.  Antithrombotic Trialists’ Collaboration: Collaborative meta-analysis  57.  Fernandez L, Mas R, Illnait J, et al: Policosanol: Results of a
                of randomised trials of antiplatelet therapy for prevention of death,  postmarketing surveillance control on 27,879 patients. Curr Ther
           © Elsevier. Es una publicación MASSON. Fotocopiar sin autorización es un delito.
                myocardial infarction, and stroke in high risk patients. BMJ   Res 59:717-722, 1998.
                324:71-86, 2002.                                58.  Meltzer J, Brignoli R, Diehm C, et al: Meta-analysis of the Tibetan
             33.  Aronow WS: Antiplatelet therapy in peripheral vascular disease.  herbal fixed formula Padma 28 in peripheral arterial disease.
                Curr Drug Targets Cardiovasc Haematol Disord 4:265-267, 2004.  Presented at the 11th Annual Symposium on Complementary
             34.  CAPRIE Steering Committee: A randomized, blinded, trial of  Health Care, Exeter, UK, November 18, 2004.
                clopidogrel versus aspirin in patients at risk of ischaemic events  59.  Sallon S, Beer G, Rosenfeld J, et al: The efficacy of Padma 28, a herbal
                (CAPRIE). Lancet 348:1329-1339, 1996.               preparation, in the treatment of intermittent claudication: a controlled
             35.  Cost information from Walgreen’s Pharmacy, Tucson, AZ, as of  double-blind pilot study with objective assessment of chronic occlusive
                December 7, 2005.                                   arterial disease patients. J Vasc Invest 4:129-136, 1998.
             36.  FDA MedWatch: Accessed from http://www.fda.gov/medwatch/  60.  Mulrow C, Lawrence V, Ackerman R, et al: Garlic: Effects on
                SAFETY/1998/ticlid2.htm on December 2, 2005.        cardiovascular risk and disease, protective effects against cancer,
             37.  Dawson DL: Comparative effects of cilostazol and other therapies  and clinical adverse effects. Evidence Report/Technology
                for intermittent claudication. Am J Cardiol 87(Suppl):19D-27D,  Assessment No. 20. (AHRQ Publication No. 01-E023). Rockville,
                2001.                                               MD, Agency for Healthcare Research and Quality, October 2000.
             38.  Jung F, Mrowietz C, Kiessewetter H, et al: Effect of Ginkgo biloba  61.  Ackermann RT, Mulrow CD, Ramirez G, et al: Garlic shows
                on fluidity of blood and peripheral microcirculation in volunteers.  promise for improving some cardiovascular risk factors.
                Arzneimittelforschung 40:589-593, 1990.             Arch Intern Med 161:813-824, 2001.
             39.  Yoshikawa T, Naito Y, Kondo M: Ginkgo biloba leaf extract: Review  62.  Jung EM, Jung F, Mrowietz C, et al: Influence of garlic powder on
                of biological actions and clinical applications. Antioxid Redox Signal  cutaneous microcirculation. A randomized placebo controlled
                1:469-480, 1999.                                    double-blind cross-over study in apparently healthy subjects.
             40.  Bauer U: Six-month double-blind randomized clinical trial of  Arzneimittelforschung 41:626-630, 1991.
                Ginkgo biloba extract versus placebo in two parallel groups in  63.  Baluchnejadmojarad T, Roghani M: Endothelium-dependent and
                patients suffering from peripheral arterial insufficiency.  -independent effect of aqueous extract of garlic on vascular reactivity
                Arzneimittelforschung 34:716, 1984.                 in diabetic rats. Fitoterapia 74:630-637, 2003.
   316   317   318   319   320   321   322   323   324   325   326